KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Inventory (2016 - 2025)

Neogenomics (NEO) has disclosed Inventory for 16 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 6.8% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 6.8%, and an annual FY2025 reading of $28.6 million, up 6.8% over the prior year.
  • Inventory was $28.6 million for Q4 2025 at Neogenomics, roughly flat from $28.5 million in the prior quarter.
  • Across five years, Inventory topped out at $34.2 million in Q2 2025 and bottomed at $20.3 million in Q1 2024.
  • Average Inventory over 5 years is $24.8 million, with a median of $24.1 million recorded in 2023.
  • The sharpest move saw Inventory decreased 20.76% in 2021, then surged 47.2% in 2025.
  • Year by year, Inventory stood at $23.4 million in 2021, then increased by 3.77% to $24.3 million in 2022, then fell by 0.5% to $24.2 million in 2023, then increased by 10.73% to $26.7 million in 2024, then rose by 6.8% to $28.6 million in 2025.
  • Business Quant data shows Inventory for NEO at $28.6 million in Q4 2025, $28.5 million in Q3 2025, and $34.2 million in Q2 2025.